Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03281889 · ClinicalTrials.gov registry record · NA

Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation

A NA study of Brain Tumor, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
20
Enrollment target
2
Study locations

NCT03281889 is a NA study of Brain Tumor that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03281889, a NA study of Brain Tumor, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

This research study is studying proton radiation as a possible treatment for brain tumor that requires radiation. The radiation involved in this study is: -Proton Radiation

Conditions Studied

Interventions

  • RADIATION Proton Beam

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2018-01-04
Est. Completion 2027-12-31
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT03281889

The ClinicalTrials.gov registry entry for NCT03281889 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (93% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which Proton Beam is the first listed.

NCT03281889 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.

Frequently Asked Questions

What is clinical trial NCT03281889 about?

NCT03281889 is a clinical study titled "Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation". This research study is studying proton radiation as a possible treatment for brain tumor that requires radiation. The radiation involved in this study is: -Proton Radiation

What is the current status of trial NCT03281889?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2018-01-04. Estimated completion is 2027-12-31.

What conditions does trial NCT03281889 study?

This clinical trial studies the following conditions: Brain Tumor.

What interventions are being tested in trial NCT03281889?

The interventions under investigation include: Proton Beam (RADIATION).

Who is sponsoring clinical trial NCT03281889?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03281889 being conducted?

This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.